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Effects of aluminum on the parathyroid hormone receptors of bone and
kidney. Aluminum intoxication is associated with low osseous remod-
eling rate and peripheral resistance to parathyroid hormone (PTH). The
pathophysiological mechanism of these aluminum induced changes was
investigated using cultured clonal osteoblastic UMR-106 cells as well as
dog renal cortical membrane. Both systems possess high-affinity PTH
receptors that are coupled to adenylate cyclase. The UMR-106 cells
have typical osteoblastic features, including receptors for the tissue-
specific hormones, formation and mineralization of a bone-like ground
substance and exclusive synthesis of type 1 collagen. The results show
that aluminum at a concentration of 4 tM and 40 kM significantly
inhibits the cyclic AMP responses to PTH challenge in UMR-106 cells,
and this is associated with significant decrease in the binding to the PTH
receptor. At 200 LM, no PTH-responsive adenylate cyclase or binding
to receptor can be demonstrated. The effect of aluminum on UMR-l06
rat osteosarcoma cells is not due to changes in cell number, cell viability
or rate of mitogenesis. Similar results are obtained with dog kidney
membrane. At a concentration of 10 rM and400 M, there is significant
inhibition of the binding of VFH to kidney membrane and proportional
decrease in PTH-stimulated adenylate cyclase. With higher concentra-
tion of aluminum, no response or binding can be demonstrated. In
conclusion, aluminum at concentrations of 4 to 400 M is associated
with a decrease in affinity of PTH receptor and concomitant suppres-
sion of PTH-stimulated adenylate cyclase. The two processes are
affected to a similar degree by different concentrations of aluminum,
and it is likely that the primary effect of aluminum is on the affinity of
the receptor which may be related to exchange of aluminum with
magnesium at 0-protein. This effect could account for the observed
peripheral resistance to PTH in aluminum intoxication as well as the
suppression of osseous remodeling rate in these patients.
Aluminum intoxication is an important cause of morbidity
and mortality in hemodialysis patients [11. Aluminum accumu-
lation in uremic patients is responsible for the development of
vitamin D resistant osteomalacia [2, 3], microcytic anemia [4],
dialysis encephalopathy [5], and generalized non-specific ill-
health [6]. The major source of aluminum is from the water used
for preparing dialysis fluid [7]. Aluminum toxicity also occurred
as a result of absorption from aluminum containing medications
[8]. The aluminum toxicity syndrome can be minimized if
special precautions in excluding aluminum from dialysis fluids
and medications are followed. Aluminum-related osteomalacia
differs from classical vitamin D-deficiency osteomalacia in that
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patients have an increased incidence of bone fractures, are
resistant to treatment with even large doses of vitamin D and
are seldom associated with secondary hyperparathyroidism [1].
Aluminum appears to affect bone formation by a direct action
on osteoblasts as well as through an action at the mineralization
front [9]. In addition, aluminum accumulation is associated with
reduced PTH secretion, which would also reduce osteoblastic
activity [10]. However, it is clear that the decrease in osteo-
blastic activity cannot be explained by changes in PTH levels
alone [9]. It has been shown by Galceran et at with isolated
perfused tibia that bones of aluminum treated dogs are resistant
to the effects of PTH [11]. It has also been shown by Lieberherr
et al that aluminum modulates the cyclic AMP responses to
PTH in a mixed culture of mouse osteoblast-like and osteoclast-
like cells [12]. To our knowledge, the possibility that aluminum
may have direct effects on the function and structure of FF11
receptors has not been evaluated. In this study, we investigate
the effects of aluminum on the function of the parathyroid
hormone receptors on osteoblasts, UMR-106 rat osteosarcoma
cells, and renal tubular membrane. UMR-l06 rat osteosarcoma
cell is a cloned and homogeneous cell line that is known to
possess typical osteoblastic features, including parathyroid
hormone [13, 14] and prostaglandin-responsive adenylate cy-
clase [15], ability to form and mineralize a bone-like ground
substance [16—18], and receptors for the tissue-specific hor-
mones [14]. Our results show that aluminum significantly inhib-
its the function of parathyroid hormone receptor on kidney and
bone cells.
Methods
Materials
Synthetic bovine PTH (1-34) was prepared by Bachem Fine
Chemicals (Torrance, California, USA) by the solid phase
procedure and had a potency exceeding 4000 U/mg. The mini-
mal essential medium used for culture of bone cells was
obtained from the Grand Island Biological Co. (Gibco, Grand
Island, New York, USA). Ten percent fetal calf serum (Gibco)
as well as penicillin (100 U/mi) and streptomycin (100 g/ml,
Gibco) were added into the medium. Tissue culture dishes and
plates were obtained from the Costar Laboratories (Van Nuys,
California, USA). All other chemicals are from standard sup-
plies. To measure the effects of various concentrations of
aluminum ion, aluminum chloride (BDH, Poole, Dorset, UK)
was included in the incubation mixture.
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Cell culture
UMR-106 rat osteosarcoma cells were grown in 25 cm2 tissue
culture flask and maintained in our laboratory as described
previously [19, 201. The cells were grown on 25 cm2 plastic
flasks in minimal essential medium, supplemented with 10%
fetal calf serum, 2 msi glutamine and 100 U/mI penicillin and
streptomycin. Aluminum at different concentrations were in-
cluded in serum-containing media during the last 24 hours of
culture to evaluate their effects.
Measurement ofcyclic AMP responses to PTH challenge in
UMR-106 clonal rat osteoblastic cells.
Confluent cultures of UMR-l06 rat osteosarcoma cells in
24-well culture plates were transferred to serum-free minimal
essential medium 24 hours before use. Incubations were initi-
ated by the addition of 150 pA of minimal essential medium
containing 20 mrvi HEPES, pH 7.4, 1 ms'i isobutyl-methyixan-
thine, and 10 pA samples of bPTH (1-34) standards in 10 mM
acetic acid with 0.1% bovine serum albumin. Incubation was
carried out at room temperature for 10 minutes and was
terminated by aspirating the medium, washing the cells with 1
ml phosphate-buffered saline and extracting cellular cyclic
AMP with three 1 ml washes of 100% ethanol. Ethanol was
subsequently evaporated in air and the extracts redissolved in
0.5 ml 50 m sodium acetate for assay. Cyclic AMP was
determined with the radioimmunoassay kit for cyclic AMP from
INCSTAR Corporation (Stiliwater, Minnesota, USA).
Preparation of['251][36Tyr]PLP(1-36) amide
PLP, a PTH-like peptide, is a polypeptide recently sequenced
by three different groups and as been shown to be of importance
in the pathogenesis of hypercalcemia of malignancy [21—23]. It
has been shown recently that iodinated PLP binds to the PTH
receptors on bone cells and thus it is a suitable ligand for the
study of PTH receptor [241.
[36Tyr]PLP(1-36) amide was iodinated by a modification of
the chloramine T procedure of Hunter and Greenwood [251. It
was from R.A. Nissenson of the University of California, San
Francisco, USA [24]. Briefly, 10 sg of PLP peptide was added
to 2 mCi of 1251 Na in 0.1 ml of 0.05 M sodium phosphate, pH
7.5. lodination was allowed to proceed for three minutes
following the addition of 0.6 g of chloramine T. Fresh chlo-
ramine T was added every 60 seconds. The reaction was
terminated by the addition of 20 pi of 1.0 m /3-mercapto-
ethanol, 20 pA of 11 mg/mI N-acetyltyrosine, and 200 pA of 10
mg/mi potassium iodide in phosphate buffer. The specific activ-
ity of the PLP peptides was about 100 CiIitg. '25I-labeled PLP
peptides were purified by chromatography over Sephadex LH-
20 followed by reverse-phase HPLC as previously described
[24, 261.
Isolation of plasma membrane fraction from canine kidney
Fresh canine kidney tissue was obtained and processed
immediately after nephrectomy as previously described [26].
The kidney specimens were sliced longitudinally and the corti-
cal tissues were dissected away from capsular tissue and fat.
The pieces of cortical tissues were homogenized with Polytron
homogenizer and Teflon pestle. The homogenate was centri-
fuged at 2,000 g for 20 minutes and, after resuspension, was
recentrifuged at 14,400 g for 20 minutes. Finally the sedimented
portion was recentrifuged at 22,000 g for 15 minutes. This
sedimented the plasma membranes as the top fluffy layer and
the mitochondrial membrane as the bottom compact layer. The
plasma membrane fraction was washed and resuspended there
times before storing at —80°C. During experiments, different
concentrations of aluminum were included in order to evaluate
their effects on the PTH receptor.
Measurement of PTH-stimulated adenylate cyclase activity in
dog kidney membrane
The PTH-stimulated adenylate cyclase activity in dog kidney
membrane was measured with the method previously described
[27]. The activity was measured by the conversion of [32P]ATP
to [32P]cAMP. Incubations were carried out in a final volume of
0.1 ml containing 0.1% BSA, 20 mM MgC12, 25 mi Tris-HC1
(pH 7.5), 0.1 mrvi [32P]ATP (100 to 300 cpm/pmol) and an ATP
regenerating system containing 30 pg creatine phosphokinase
and 12 msi creatine phosphate.
Incubations were initiated by adding plasma membrane (25
g protein) in 25 pA SET buffer or buffer alone for blank assay
measurement. After 30 minutes of incubation at 30°C, the
reaction was terminated by the addition of 100 pA solution
containing 50 mM Tris-HCI (pH 7.5), 2% SDS, 10 m unlabeled
ATP and 1 m'vi [3H]cAMP (50,000 cpm).
The tubes were immediately placed in a boiling water bath for
three minutes to stop the reaction. The [32P]cAMP was subse-
quently isolated by the chromatography procedure. Column
effluents containing cAMP was mixed with scintillant and the
radioactivity was measured using a dual isotope program. All
values were corrected for the recovery of [3H]cAMP, which
was consistently higher than 70%.
Preparation of['251]bPTH(1-34)
bPTH(l-34) was radiolabeled using the lactoperoxidase
method. Lactoperoxidase (grade B, 20.3 lU/mg, Calbiochem,
La Jolla, California, USA) was used as a catalyst and a molar
ratio of bPTH (1-34), Na 125! (Amersham, Buckinghamshire,
UK) and H202 (Fisher, Pittsburgh, Pennsylvania, USA) of 2:1:1
was used. The iodination by lactoperoxidase technique pro-
ceeds at room temperature in 0.1 M sodium phosphate buffer,
pH 7.0. The reaction was stopped by adding 100 mri dithiothre-
itol (Sigma Chemical Co., St. Louis, Missouri, USA), and the
reactants were incubated at room temperature for 60 minutes.
There was approximately 60% incorporation of radioactive
iodine into protein as measured by the precipitation of aliquots
of the reaction mixture with 20% trichloroacetic acid.
After labeling, labeled and unlabeled hormones were then
separated by chromatography techniques to achieve maximal
specific activity as previously described [281. The products of
labeling were initially extracted using Sep-Pak C18 cartridge
(Waters Scientific, Mississauga, Ontario, Canada). After load-
ing, reactants of the iodination procedure and unused Na 125!
were removed by 20 ml of 0.1% trifluoroacetic acid. Elution of
the labeled hormone was subsequently achieved with 3 ml of
80% acetonitrile containing 0.1% trifluoroacetic acid.
The eluates were further purified by high performance liquid
chromatography and loaded onto a C18 uBondapak column
(Waters Scientific), pre-equilibrated with 0.1% trifluoroacetic
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Aluminium
chloride
UMR-106 cells
at 80% confluence
mitogenesis
UMR-106 cells
at 100% confluence
mitogenesis
OM 100% 100%
10—6 M 100.2% 99.2%
4 x l0 M 101 .3% 98.2%
2 x l0 M 98.1% 99.1%
1O M 99.2% 100.2%
acid in water. The peptides were subsequently eluted with 0 to
95% gradient of N-propanol in 0.1% trifluoroacetic acid.
Measurement of binding of 125jbPTH (1-34) to dog kidney
membrane
Dog kidney membrane in 10 1.d ice cold SET (0.25 M sucrose,
1 mM EDTA, 5 mri Tris, pH 7.5) buffer was added to an
incubation mixture containing a final concentration of 50 mt
Tris, 50 mM Hepes (pH 7.5), 2 mM MgC12, 0.1% BSA, 10,000
cpm ['251]-bPTH (1-34) together with unlabeled bPTH (1-34) of
appropriate concentrations to make up a final volume of 100 d
in 1.5 ml microcentrifuge tube. The mixture was incubated for
one hour at 30°C. At the end of this period, the binding reaction
was stopped by diluting with 1 ml ice cold SET. The tube was
then centrifuged for five minutes at 4°C. After aspiration, the
pellet was counted for gamma rays. The readings were com-
pared with total count, blank (incubation mixture without
membrane and unlabelled bPTH (1-34)), and non-specific bind-
ing, which was measured in the presence of 250 nM bPTH
(1-34). The specific binding was the difference between total
binding and non-specific binding.
To measure binding in the presence of aluminum ion, alumi-
num chloride (BDH) was included in the incubation mixture so
as to make the final concentration of aluminum at 10 LM, 400
M and 1000 LM, respectively.
Measurement of the effects of aluminum on the mito genesis
of UMR-106 rat osteosarcoma cells
Rat osteosarcoma UMR-106 cells were seeded in 24-well
cluster plates (Costar, Van Nuys, California, USA) at a con-
centration of 1 x iO cells/well. Different concentrations of
aluminum (Table 1) were added and incubated for 24 hours at
37°C in 5% CO2 and 95% air. [3H]-thymidine (0.5 tCiIml)
(Amersham International, Buckinghamshire, UK) was included
during the last six hours of incubation with aluminum. The
reaction was terminated by aspiration of medium. The cultures
were subsequently washed with ice-cold phosphate-buffered
saline containing 1 mM thymidine. After washing, UMR-106
cells were trypsinized and transferred to centrifuge tubes con-
taining equal volumes of 0.1% BSA in distilled water and
precipitated by ice-cold TCA. After one-half hour at 4°C, tubes
were centrifuged for 30 minutes and supernatants were dis-
carded. The pellet was dissolved in 0.1 M sodium hydroxide.
Mitogenesis as measured by [3H]-thymidine incorporation was
determined by scintillation counting.
Binding of ['251]-PLP(1-36)-amide to UMR-106 rat
osteosarcoma cells
Binding of labeled ligands to UMR- 106 cells was measured on
confluent cells in 24-well cluster plates, as previously described
[24]. Briefly, confluent cells were incubated at 37°C in serum-
free MEM-EBSS for one hour. One hundred and fifty microli-
ters of MEM-EBSS containing 20 mri HEPES, 1 x iO cpm of
labeled PLP and unlabeled peptides, was then added. Incuba-
tions were carried out at room temperature for one hour to
achieve the steady state. The medium was saved for measure-
ment of unbound counts. Following removal of medium, the
cells were washed three times with 1.0 ml of ice-cold PBS and
were subsequently scraped from the dishes in 0.8 M NaOH for
gamma counting.
Statistical analysis
Unless otherwise specified, the data were obtained from
representative experiments which were performed three times.
The data are presented as the mean standard error of the
mean of triplicate assays for each condition in the cell popula-
tion. The significance of difference between groups was deter-
mined by analysis of variance as well as by the Student's t-test.
A P value of less than 0.5 was taken as significant.
Results
Effect of aluminum on the cyclic AMP responses to PTH in
UMR-106 rat osteosarcoma cells
Incubation with aluminum at 4 M, 40 /LM and 200 M was
performed as described. The results are shown in Figure 1. The
cyclic AMP responses to PTH challenge were significantly
impaired in the presence of 4 M and 40 tLM aluminum and were
nearly undemonstrable in the presence of 200 tM aluminum.
Effect of aluminum on the binding of ['251]PLP(1-36) amide to
UMR-106 rat osteosarcoma cells
Incubation with aluminum at 40 M, 40 J.M and 200 tM was
performed as described. The results are shown in Figure 2. In
the presence of 4 M and 40 j.tM of aluminum, the binding of
['251]PLP(1-36) amide to UMR-106 rat osteosarcoma cells was
significantly impaired. In the presence of 200 pM aluminum, no
binding could be demonstrated at all.
Effect of aluminum on the adenylate cyclase response of dog
kidney membrane to PTH challenge
Figure 3 shows the results of the adenylate cyclase response
of dog kidney membrane to PTH challenge. In the presence of
aluminum at 10 /.LM and 400 M, the adenylate cyclase response
was significantly impaired. In the presence of 1000 M alumi-
num, the adenylate cyclase response to PTH challenge was
barely demonstrable.
Effect of aluminum on the binding of ['251]bPTH(I-34) to dog
kidney membrane
Figure 4 shows the results. In the absence of aluminum, the
PTH receptor on dog kidney membrane had an affinity of 2 nM
and was present at a concentration of 2.2 pmol/mg protein. In
the presence of 10 sM and 400 M aluminum, the affinity of
P1'H receptor decreased significantly. In the presence of 1000
/LM aluminum, no binding activity could be demonstrated.
Table 1. Effects of aluminium on the mitogenesis of UMR-106
bone cells
Different concentration of aluminium were used to incubate with
UMR-106 cells and the mitogenesis was quantitated with cells at 80%
and 100% confluence. The baseline value of mitogenesis (buffer only)
was taken as 100%.
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Fig. 2. Effect of aluminum on the binding of['25!JPLP(1-36) amide to UMR-106 rat osteosarcoma cells. Similar to the results observed in Figure
1, the binding of ['251]PLP(1-36) amide was significantly impaired in the presence of 4 M and 40 LM of aluminum (P < 0.05), and was undetectable
in the presence of 200 M. Scatchard analysis (inset) shows that there was significant decrease in the slope (affinity of receptor) with increasing
concentrations of aluminum (P < 0.05).
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Fig. 1. Effect of aluminum 40 /.LM and 200 /.LM on
the cyclic AMP responses to parathyroid
hormone stimulation in UMR-106 rat
osteosarcoma cells. Incubation with aluminum 4
sM, 40 /LM and 200 /LM was performed as
described. The cyclic AMP responses to PTH
challenge were significantly impaired in the
presence of 4 M and 40 M aluminum (P <
0.05) and were undetectable in the presence of
200 /J.M.
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Fig. 4. Effect of aluminum on the kidney of['251]bPTH(1-34) to dog kidney membrane. In the presence of 10 LM and 400 sM aluminum, the affinity
of PTH receptor decreased significantly (P < 0.05). In the presence of 1000 j.M aluminum, no receptor could be demonstrated. Scatchard analysis
(inset) shows that there was significant decrease in the slope (affinity of receptor) with increasing concentrations of aluminum (P < 0.05).
Effects of aluminum on the mitogenesis of UMR-106 rat cells. The results are shown in Table 1. Aluminum did not have
osteosarcoma cell any significant effect on the mitogenesis of bone cells when
tested with cultures at two different stages of confluence. The
Different concentrations of aluminum ions were used for number of viable cells as measured by trypan blue exclusion
incubation to assess their effects on the mitogenesis of bone was also comparable.
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Fig. 3. Effect of aluminum on the adenylate
cyclase response of dog kidney membrane to
PTH challenge. In the presence of aluminum
10 /LM and 400 M, the adenylate cyclase
response was impaired by fourfold (P < 0.05).
In the presence of aluminum 1000 LM, the
adenylate cyclase response to VFH challenge
was barely detectable.
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Discussion
Studies on the pathogenesis of aluminum intoxication have
shown that the bone aluminum content is substantially in-
creased in uremic patients, especially among those undergoing
treatment with hemodialysis [29—31]. The cellular and molecu-
lar mechanism by which aluminum affects mineralization and
induces osteomalacia is unknown. It is important to define the
factors which regulate the skeletal accumulation of aluminum
and to identify the effects of aluminum on bone to formulate
strategy for the treatment of aluminum toxicity.
Our results show that aluminum at 4 M, 40 tM and 200 M
significantly impaired the cyclic AMP response to PTH chal-
lenge in UMR-106 rat osteoblastic cells and at 10 p.M, 400 /LM
and 1000 M in dog kidney membrane (Figs. 1 and 3). Because
of the high protein concentration in the culture media and in the
dog kidney membrane preparation, it is likely that much of
aluminum is protein-bound. In association with this decrease in
response, aluminum at similar concentrations significantly im-
paired the binding of 1125-PLP to PTH receptors on the UMR-
106 rat osteosarcoma cells and the binding of I'25-bPTH (1-34)
to PTH receptors on the dog renal tubular membrane. In both
systems, aluminum at a lower concentration decreased the
affinity of PTH receptors significantly, while aluminum at a
higher concentration was associated with no demonstratable
binding at all.
The I'25-bPTH (1-34) was prepared with lactoperoxidase
method and bound with high affinity and specificity to PTH
receptor on dog kidney membrane. However, it did not bind to
PTH receptor on rat bone cells. This may be due to oxidative
damage to PTH during iodination. Production of bioactive,
radiolabeled PTH is especially difficult because of the presence
of labile amino acids at bioactive sties. In this study, a similar
peptide, PTH-like peptide, which has recently been cloned,
bound to PTH receptor with high affinity and specificity [21—24].
Thus I'25-PLP( 1-36) amide was used for characterization of the
PTH receptors on bone cells after aluminum intoxication.
The above effects on PTH receptor are unlikely to be due to
non-specific toxic effects on cells. Indeed, the observed effects
of aluminum in the system of dog kidney membrane show that
the toxicity acts directly on membrane proteins and cannot be
explained by non-specific injury to the cells. The lack of
suppressive effect of aluminum on the mitogenesis of bone cells
further shows that aluminum at the concentrations used does
not significantly suppress cellular function and division. Thus
the observed effects of aluminum cannot be due to a decrease in
cell number. Control experiments (data not shown) also show
that aluminum does not have any action on insulin receptor of
bone cells, and lead and copper do not have actions on PTH
receptor of bone cells. These data show that the effects of
aluminum on PTH receptors are specific toxic actions.
The above results demonstrate that the effect of aluminum on
cyclic AMP responses to PTH is closely associated with
changes in the binding affinity of the PTH receptors. The direct
explanation of these conjoint changes is that aluminum interacts
with the PTH-receptor adenylate-cyclase complex to decrease
the binding with ligand and, as a result, the associated activa-
tion of adenylate cyclase is decreased. PTH receptor is one of
the peptide hormone receptors, and the exact amino acid
sequence is not yet known [32]. Like the other peptide hormone
receptors, PTH-receptor adenylate-cyclase complex consists of
three different components, namely receptor moiety, G-protein
and adenylate cyclase [32]. The receptor moiety is known to be
a polypeptide of 70 to 80 kDa in molecular weight and probably
has structural homology to other peptide hormone receptors
which are coupled to G-protein [33]. The G-protein has an
important regulatory function. It binds guanyl nucleotides in the
presence of the important cofactor, magnesium, and couples
receptor occupancy to the activation of adenylate cyclase, with
release of cyclic AMP into the cytoplasm [33]. The G protein is
converted by GTP binding into an active form that is associated
with the enzymatic catalytic unit, stimulating the conversion of
ATP to cyclic AMP. Subsequently, the GTP-degrading activity
associated with the G-protein causes its deactivation by con-
verting the bound GTP to GDP and favoring its dissociation
from the C unit [33]. In all G-protein-linked receptors, magne-
sium is an essential co-factor for its function [33]. In fact, the
substrate for adenylate cyclase is Mg-ATP and not ATP per Se.
Because the effective ionic radii for aluminum and magne-
sium are comparable, aluminum substitution for magnesium in
physiological settings is a common pathogenetic mechanism for
aluminum toxicity [34]. On the other hand, aluminum substitu-
tion for calcium is highly unlikely because the effective ionic
volume of calcium is nine times greater than that of aluminum
[34]. As magnesium has important role in the formation of the
ternary PTH-receptor-Gs complex that is required for PTH-
activation of adenylate cyclase, the removal of magnesium from
the incubation medium used for adenylate cyclase assay would
lead to loss of activity. The substitution of magnesium by
aluminum would lead to similar loss of action and prolonged
inactivation as the dissociation kinetics for aluminum is slow.
The end results would be similar to those obtained in this study,
namely loss of PTH-activated adenylate cyclase activity and
loss of high-affinity binding sites for PTH. This could account
for the loss of PTH-induced release of cyclic AMP for both in
vivo and in vitro models [35].
To conclude, aluminum markedly suppresses the ligand bind-
ing and the action of PTH receptors in both rat bone cells and
dog kidney membrane. This is the likely pathogenetic mecha-
nism underlying the observed peripheral resistance to PTH as
well as the suppression of osseous remodelling rate in aluminum
intoxication.
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